Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

May 4, 2011

Primary Completion Date

January 3, 2018

Study Completion Date

January 3, 2018

Conditions
Lysosomal Acid Lipase DeficiencyWolman Disease
Interventions
DRUG

Sebelipase alfa (SBC-102)

Sebelipase alfa is a recombinant human lysosomal acid lipase enzyme. The investigational medicinal product is an enzyme replacement therapy intended for treatment of participants with LAL Deficiency. Dosing occurred qw for up to 5 years.

Trial Locations (7)

1

Dublin

11771

Cairo

38700

Grenoble

75015

Paris

92697

Irvine

SE1 7EH

London

M13 9WL

Manchester

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY